相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
Peter Schotland et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
Theodoros G. Soldatos et al.
MEDICINA-LITHUANIA (2019)
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
Christos Sachpekidis et al.
PHARMACEUTICALS (2019)
Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities
Peter Schotland et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Improving drug safety with a systems pharmacology approach
Peter Schotland et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
Luc Rochette et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer
F. B. Silva et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2015)
Prevention of Anthracycline-Induced Cardiotoxicity
Pimprapa Vejpongsa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Cell-Based Screening Identifies Paroxetine as an Inhibitor of diabetic Endothelial Dysfunction
Domokos Geroe et al.
DIABETES (2013)
Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies
Rui Adao et al.
REVISTA PORTUGUESA DE CARDIOLOGIA (2013)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Adriana Albini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Catherine M. Kelly et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Catalase and glutathione peroxidase mimics
Brian J. Day
BIOCHEMICAL PHARMACOLOGY (2009)
Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways
Leo I. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Quantitative signal detection using spontaneous ADR reporting
A. Bate et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
N. Lynn Henry et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells
Scott A. Shell et al.
CELL CYCLE (2008)
Therapy insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects
Sanjay Popat et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation
Marie H Hanigan et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats
Rauf Onur Ek et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2008)
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
Neil L. Spector et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Data mining for signals in spontaneous reporting databases: proceed with caution
Wendy P. Stephenson et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses
M Golding et al.
PSYCHOPHARMACOLOGY (2005)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
WL Xia et al.
ONCOGENE (2005)
Estrogen inhibits cardiomyocyte hypertrophy in vitro -: Antagonism of calcineurin-related hypertrophy through induction of MCIP1
A Pedram et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
A Argiris et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiornyocytes - Implications for herceptin-induced cardiomyopathy
LP Grazette et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Trastuzumab plus tamoxifen:: anti-proliferative and molecular interactions in breast carcinoma
S Ropero et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer:: what can be expected and why?
A Jones
ANNALS OF ONCOLOGY (2003)
Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures
VK Yeragani et al.
BIOLOGICAL PSYCHIATRY (2002)
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
SJW Evans et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2001)
Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes
T Kakita et al.
CIRCULATION RESEARCH (2001)
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo - An apoptosis-independent model of dilated heart failure
LJ De Windt et al.
CIRCULATION RESEARCH (2000)
分享论文
